Date: 2017-05-04
Type of information: Nomination
Compound: president and chief executive officer
Company: Crispr Therapeutics (Switzerland - UK)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On May 4, 2017, CRISPR Therapeutics, a biopharmaceutical company focused on developing gene-based therapeutics for patients with serious diseases, has promoted Dr. Samarth Kulkarni, Ph.D. to the role of President and Chief Business Officer. The new role reflects his increased responsibilities in leading the strategic direction of the company and overseeing its U.S. operations. Dr. Kulkarni will continue to lead strategy, business development, investor relations and external communications in his expanded role.
- Over the past two years as Chief Business Officer, Dr. Kulkarni had a leading role in the establishment of its keycollaborations with Vertex and Bayer, and played a major part in helping finance the company’s operations through its IPO.
- CRISPR Therapeutics’s lead program, which aims to provide a functional cure for beta thalassemia and sickle cell disease, is on track and the company is planning to file for a clinical trial authorization in Europe by the end of 2017.
Financial terms:
Latest news:
Is general: Yes
